Skip to main content
. 2017 Aug 28;4(2):233–246. doi: 10.1007/s40744-017-0076-0

Fig. 3.

Fig. 3

Comparison of percentage of patients without symptoms of enthesitis and dactylitis in the FUTURE-2 trial at week 52 versus baseline using observed data (Mease et al. [5])